Ask AI

Closing Practice Gaps in SM: The Latest Advances in SM Management for APPs

Video
This activity is available for 0.50 CME/CE credit(s).

Released: August 20, 2026

Expiration: August 19, 2027

See Activity Collection

Early recognition and effective management of systemic mastocytosis (SM) require advanced practice providers to think beyond the skin, as systemic symptoms often present alongside cutaneous involvement. Learn how to better recognize SM in your practice by understanding its heterogeneous clinical presentations, how it differentiates from other mast cell disorders, and the diagnostic criteria that must be met to confirm a diagnosis.

Closing practice gaps in SM 2

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

How many people with systemic mastocytosis do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

A 48-yr-old male patient with KIT D816V–positive indolent systemic mastocytosis continues to experience worsening flushing, pruritus, and diarrhea despite 6 mo of optimized antimediator therapy.

During a discussion about treatment options, the patient expresses interest in avapritinib. Which statement about its efficacy is best supported by clinical trial evidence?